文献速递肾小球疾病

硼替佐米-环磷酰胺-地塞米松对比利妥昔单抗治疗PGNMID的初步随机试验

Bortezomib-Cyclophosphamide-Dexamethasone versus Rituximab in PGNMID -Dexamethasone versus Rituximab in PGNMID.
PubMed 文献 · Nephrol Dial Transplant · 2026-06-23

这项单中心、开放标签、初步随机对照试验纳入20例伴单克隆免疫球蛋白沉积的增生性肾小球肾炎(PGNMID)患者,1:1随机接受BCD方案或利妥昔单抗。12个月时总体肾脏缓解率BCD组60%(6/10)、RTX组70%(7/10),差异无统计学意义(P=1.0)。两组蛋白尿均下降、血清白蛋白均改善,安全性总体可控。

要点

  • BCD与利妥昔单抗在PGNMID中均观察到肾脏缓解,12个月缓解率分别为60%与70%。
  • BCD组6个月时eGFR出现一过性下降,至12个月恢复。
  • BCD组发生1例严重不良事件(肺炎),安全性总体可控。

核心结论

  • 在这项探索性初步试验中,BCD方案与利妥昔单抗均与PGNMID患者的肾脏缓解相关,结果具有假设生成性。

研究设计与样本

  • 单中心、开放标签、初步随机对照试验,20例合格患者按1:1随机接受6周期BCD或利妥昔单抗375 mg/m²每周4次。
  • 对B细胞重建>5/μL的患者,按预设方案在6个月时给予500 mg利妥昔单抗加强剂量。
  • 主要疗效终点为12个月时总体肾脏缓解,次要结局包括6和12个月时蛋白尿、血清白蛋白和eGFR变化。

主要发现

  • 意向性治疗分析(n=20)中,12个月总体肾脏缓解率BCD组为60%(6/10),RTX组为70%(7/10),P=1.0。
  • 治疗失败在BCD组发生2例,RTX组无。
  • 6个月时完全缓解在BCD组有5例、RTX组有3例。
  • 两组在12个月内均显示蛋白尿下降和血清白蛋白改善;BCD组6个月时eGFR一过性下降,12个月恢复。
  • BCD组发生1例严重不良事件(肺炎)。

临床怎么用

  • 在缺乏前瞻性对照证据的PGNMID中,BCD和利妥昔单抗均可作为克隆导向治疗的候选方案,但需个体化评估。
  • BCD治疗期间需监测eGFR变化及感染风险,本试验中观察到一过性eGFR下降和1例肺炎。

局限性

  • 样本量小(20例),开放标签设计,治疗暴露结构不同,结果仅为假设生成性。
  • 需要更大规模、多中心、更长随访的研究来确定PGNMID的最佳治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a rare renal disorder for which prospective controlled treatment evidence is limited. Clone-directed therapies targeting plasma cells or B cells are increasingly used, but comparative prospective data are lacking. METHODS: This single-center, open-label, pilot RCT aimed to evaluate the feasibility and preliminary efficacy of plasma cell-targeted therapy (bortezomib-cyclophosphamide-dexamethasone, BCD) versus B-cell-targeted therapy (rituximab, RTX). Twenty eligible patients were randomized (1:1) to receive either 6 cycles of BCD or 4 weekly doses of rituximab at375 mg/m². In patients with B-cell reconstitution > 5/μL, a 500 mg rituximab booster dose was administered at 6 months according to the prespecified protocol. The primary efficacy endpoint was overall renal response at 12 months. Changes in proteinuria, serum albumin and estimated glomerular filtration rate were also assessed at 6 and 12 months as secondary outcomes. Safety outcomes included infections and hematologic toxicity. RESULTS: Baseline characteristics were generally comparable between groups. The median age was 57 years, and mean proteinuria 4.1 ± 3.1 g/d. In the primary intention-to-treat analysis (n = 20), the primary outcome of overall renal response at 12 months was observed in 60% (6/10) of patients in the BCD group and 70% (7/10) in the RTX group (P = 1.0). Treatment failure occurred in 2 patients in the BCD group and none in the RTX group. At 6 months, complete response occurred in five patients in the BCD group and three patients in the RTX group. Both groups showed reductions in proteinuria and improvements in serum albumin over 12 months. A transient decline in estimated glomerular filtration rate was observed in the BCD group at 6 months and recovered by 12 months. Safety profiles were manageable, with one serious adverse event, pneumonia, in the BCD group. CONCLUSION: Both BCD and rituximab were associated with renal responses in this exploratory pilot trial of PGNMID. Given the small sample size, open-label design, and differences in treatment exposure structure, these findings are hypothesis-generating. Larger multicenter studies with longer follow-up are needed to define optimal therapy for PGNMID.Trial registration: chictr.org.cn Identifier: ChiCTR2500102928.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Zhang X, Yu XJ, Wang Z, et al. Bortezomib-Cyclophosphamide-Dexamethasone versus Rituximab in PGNMID -Dexamethasone versus Rituximab in PGNMID. Nephrol Dial Transplant. 2026. PMID: 42335939. doi:10.1093/ndt/gfag146

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。